No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients
How to Cite
OrthoEvidence. No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients. ACE Report. 2021;20(1):4. Available from: https://myorthoevidene.com/AceReport/Report/13409
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19N Engl J Med. 2021 Mar 11;384(10): 905-914.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Three hundred and fourteen hospitalized patients with COVID-19 were randomized to receive a single intravenous infusion of LY-CoV555 antibody therapy (n=163) or placebo (n=151) for the improvement of recovery and reduction of adverse events. The primary outcomes of interest was sustained recovery (discharged home and remaining at home for at lest 14 days) and a composite safety outcome of death, s...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE